Pō a Ao Healing Sanctuary

01 · Understanding the medicine

What is 5-MeO-DMT / Bufo?

5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine) is a potent psychedelic tryptamine found in some plants and in the secretion of the Sonoran Desert toad, Incilius alvarius (formerly Bufo alvarius). “Bufo” is not a standardized medicine: toad secretion contains 5-MeO-DMT plus other biologically active compounds, including cardiac glycosides and catecholamines, with variable composition 2. Synthetic 5-MeO-DMT is distinct from whole secretion. Effects can begin rapidly and include major changes in perception, emotion, body awareness, and sense of self. Human therapeutic evidence remains preliminary: a 2024 systematic review found only three eligible clinical trials with 78 participants, two in healthy volunteers and one in treatment-resistant depression, with short follow-up and no serious adverse events 1. These findings do not establish efficacy or safety for the general public.

02 · The science

How it works

The compound primarily activates serotonin 5-HT1A and 5-HT2A receptors, with additional serotonin-system activity; its active metabolite bufotenine is formed partly through CYP2D6 metabolism. MAO-A is an important inactivation pathway 2. These mechanisms may alter network activity and emotional processing, but proposed neuroplastic, anti-inflammatory, or antidepressant effects remain hypotheses rather than established clinical mechanisms. Intense, short-lived experiences may include ego dissolution and mystical-type phenomena; these are descriptions of subjective experience, not proof of therapeutic benefit.

03 · Hope, with context

What researchers are exploring

Potential benefit is not a promised outcome. The study population, support, setting, and evidence quality all matter.

Rapid changes in mood symptoms

Early studies and surveys have reported reductions in depression, anxiety, and stress after naturalistic use, and a small early-phase program has studied people with treatment-resistant depression. Findings cannot separate drug effects from expectancy, selection, context, or post-session support 1 2.

Preliminary observational and early-phase evidence; efficacy is not established.

Source 1 Source 2

Brief administration window

Compared with longer-acting classic psychedelics, inhaled 5-MeO-DMT has a relatively short acute experience. Researchers are investigating whether this could make supervised research more practical; shorter duration does not mean lower intensity or lower risk 2.

Pharmacology and feasibility rationale, not a demonstrated patient benefit.

Source 2

Subjective meaning-making

Participants and observational cohorts sometimes describe unity, reverence, emotional release, or altered self-understanding. Such experiences can be meaningful while also being difficult, confusing, or destabilizing; they should not be presented as guaranteed healing 2.

Self-report and naturalistic evidence; vulnerable to bias and incomplete follow-up.

Source 2

04 · Informed decisions

Safety & medication interactions

Do not start, stop, combine, or taper medicines based on this page. Discuss your complete medication list and health history with your prescriber or pharmacist.

Acute cardiovascular stress

Clinical studies observed transient increases in heart rate and blood pressure, with headache, nausea, chest discomfort, and other physical effects reported 1. Toad secretion adds variable cardioactive compounds, so its risk profile cannot be inferred from purified synthetic material 2.

Source 1 Source 2

Psychiatric destabilization

The experience can involve intense fear, confusion, agitation, impaired judgment, or overwhelming loss of self-boundaries. Screening in trials excludes many people with medical or psychiatric vulnerability; rare or delayed mania, psychosis, persistent perceptual symptoms, or suicidality remain incompletely characterized.

Source 1 Source 2

Interaction and toxicity uncertainty

MAO-inhibiting drugs or plants may reduce metabolism and increase exposure, potentially producing prolonged or hyperserotonergic effects 2. Other serotonergic, sympathomimetic, cardiovascular, psychiatric, and CYP2D6-affecting medicines may also require specialist review. Do not stop or change prescribed medicines without the prescriber.

Source 2

Material and setting hazards

Whole toad secretion is chemically variable and may be contaminated or misidentified; altered consciousness also increases risk of injury, aspiration, coercion, or inadequate emergency response. Research findings from screened adults in controlled settings do not generalize to unsupervised use.

Source 1 Source 2

Interaction considerations

Potentially dangerous interactions include MAO inhibitors, serotonergic medicines or supplements, stimulants, and drugs affecting blood pressure, heart rhythm, or CYP2D6 metabolism. The evidence base does not define universally safe combinations or waiting periods. A qualified clinician or pharmacist who knows the complete medication, supplement, and health history is the appropriate source for individualized risk review; this entry is not a treatment protocol.

Explore the Safety Center

05 · The wider story

History, culture & legal context

“Bufo” can refer to a toad-derived preparation, while 5-MeO-DMT may be synthetic or plant-derived; these are not interchangeable. Accounts of Indigenous and other living ceremonial relationships with psychoactive plants or animals should not be collapsed into a single “Bufo tradition,” and modern commercial ceremonies are not automatically Indigenous practices. Cultural teachings, consent, reciprocity, ecological stewardship, and community accountability are separate from clinical evidence and should be discussed respectfully without claiming traditional authority.

Legal context

In the United States, the DEA’s 2024 resource guide lists 5-MeO-DMT as a Schedule I controlled substance 3. Laws differ by country, state, territory, and sometimes by source material; possession, preparation, administration, importation, and facilitation may carry separate consequences. ClinicalTrials.gov records 5-MeO-DMT studies as research, not as proof of regulatory approval; the cited phase 1 study was not an FDA-regulated drug product 4. Check current official law where you live.

06 · Beyond the experience

Preparation & integration

Before

There is no established self-care preparation standard. In research, preparation includes eligibility screening, informed consent, physical and psychiatric assessment, medication review, trained monitors, emergency planning, measured investigational material, and protected aftercare. Anyone considering participation should verify ethics oversight, qualifications, transparent consent, safeguarding, confidentiality, and emergency capability; do not use this page to obtain, measure, or combine substances.

After

Integration may involve rest, hydration as medically appropriate, journaling, trusted social support, and reflective or psychotherapeutic conversations, while recognizing that evidence for any particular integration method is limited. Seek urgent medical help for chest pain, severe agitation, high fever, seizure, fainting, dangerous confusion, or thoughts of self-harm. Persistent distress, insomnia, mania, psychosis, or perceptual changes warrant prompt professional assessment.

Questions to bring to your care team

Is this purified synthetic 5-MeO-DMT or variable toad secretion, and how are identity, contaminants, and dose verified?
What medical and psychiatric screening, medication review, consent, monitoring, safeguarding, and emergency plan are in place?
What follow-up is available if distress, mania, psychosis, cardiovascular symptoms, or persistent perceptual changes occur?

Preparation guide →Integration support →

07 · Follow the evidence

Sources & further reading

Read the original work. Publication is not endorsement, and a source check is not independent clinical review.